Role of extracorporeal photopheresis in the management of children with graft‐vs‐host disease

• Published in: Journal of clinical apheresis Vol. 37; no. 6; pp. 573 - 583
• Main Authors: Asensi Cantó, Pedro, Sanz Caballer, Jaime, Fuentes Socorro, Carolina, Solves Alcaína, Pilar, Lloret Madrid, Pilar, Solís Ruíz, Jürgen, Torres Guerola, Bárbara, Rubia Comos, Javier, Fernández Navarro, José María, Gómez‐Seguí, Ines
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.12.2022; Wiley Subscription Services, Inc
• Subjects: Apheresis; children; extracorporeal photopheresis; graft‐versus‐host disease; Multivariate analysis; Photodynamic therapy; Stem cell transplantation
• ISSN: 0733-2459; 1098-1101; 1098-1101
• DOI: 10.1002/jca.22012

Introduction Graft‐vs‐host disease (GVHD) is a frequent cause of morbidity and mortality in allogeneic stem cell transplants. Extracorporeal photopheresis (ECP) is one of the most accepted second‐line treatments, but technical issues of ECP in children might be prohibitive. Materials and Methods Patients under 18 y of age with corticodependant or corticorefractory GVHD receiving ECP at our hospital were included in this retrospective study. ECP was performed with an in‐line system (CellExTherakos) in 2013‐2014 and with an off‐line system (Spectra Optia) from 2015 onwards. Cumulative incidence curves were obtained to compare ECP efficacy among patients grouped by different baseline, apheresis, and disease characteristics. Significant variables on univariate analysis (Gray's test) were pooled into a multivariate analysis (Fine‐Gray proportional hazard regression for competing events). Results A total of 701 ECP sessions were performed on 33 patients between October 2013 and December 2021. In total, 97% of the sessions could be executed. In 8% of the sessions an incident was detected, most of them mild and related to catheter dysfunction. With a median follow‐up for alive patients of 33.6 mo (range, 8‐95), the composite partial and complete response cumulative incidence was 70% (95% confidence interval, 51%‐82%) and the median time to maximal response was 2.8 mo (range, 0.25‐9.8). Significantly lower response ratios were found in patients with hepatic, gastrointestinal, acute, or severe GVHD. The only variable that influenced response on multivariate analysis was GVHD severity. Discussion ECP is feasible, safe, and effective for pediatric patients with corticorefractory or corticodependant GVHD, offering a less toxic and nonimmunosuppressive treatment option.